Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting ...

Boston Scientific markets a broad portfolio of internally-developed and self-manufactured drug eluting stents including the Promus PREMIER, Promus Element and Promus Element Plus everolimus-eluting ...

Buy the report here. The PROMUS ELEMENT PLUS is sold by Boston Scientific in the Coronary Stents – DES market. Drug eluting stents (DES) release drugs locally and can be coated with a polymeric ...

According to GlobalData, PROMUS ELEMENT PLUS is one of 45 product lines sold in the US coronary stents market; these product lines are sold by 8 different manufacturers. The price of the PROMUS ...

the Promus Element Plus. That study found that Synergy was "non-inferior" to the older stent in a medically complex population of patients. Weeks after Synergy's approval, Boston Scientific CEO ...

NEW ORLEANS and MARLBOROUGH, Mass., May 12, 2017 /PRNewswire/ -- New analyses from the Boston Scientific Corporation (NYSE: BSX) sponsored PLATINUM Diversity study underscore the need for greater ...

Batchelor said the impetus for PLATINUM Diversity stemmed in part from past studies that showed a higher rate of stent thrombosis ... were pooled with the Promus-Element Plus Post Approval Study ...

An interventional cardiologist at the Christ Hospital, he was also a principal investigator in Boston Scientific’s 1,684-patient Evolve II trial, comparing the Synergy bioresorbable-polymer stent with ...

“In this pivotal, noninferiority trial … the Synergy stent proved noninferior to the Promus Element Plus stent for [target lesion failure] at 1 year,” Kereiakes said. “Despite the clinical ...